Abstract 5255
Background
PD-1/PD-L1 blockades have shown promising antitumor activity in clinical trials of advanced nasopharyngeal carcinoma (NPC). Being the most wildly used molecular imaging in clinic, 18F-FDG PET/CT provides multiple information of tumor biology. In this study, we investigated the association of PD-L1 expression with 18F-FDG uptake and clinical features in patients with NPC.
Methods
84 patients were initially histopathologically diagnosed with NPC between December 2016 and March 2019. All tissue specimens and PET/CT images were collected before any treatment. The PD-L1 antibody we used in this investigation was SP263 (Ventana, USA). High PD-L1 expression in tumor cells (TC) or tumor-infiltrating immune cells (TIIC) was defined as ≥ 50% of corresponding cells with membranous staining.
Results
The values of tumor SUVmax and TLG in patients with positive TC PD-L1 expression were significantly higher than those of negative TC PD-L1 expression (SUVmax: 10.3±4.1 vs. 6.9±3.2; P < 0.001; TLG: 77.7±64.5 vs. 35.0±20.5; P < 0.001), while the SUVmax values and TLG in patients with positive TIIC PD-L1 expression is lower than those of negative TIIC PD-L1 expression (SUVmax: 7.0±3.4 vs. 9.7±4.1; P = 0.011; TLG: 29.1±14.4 vs. 71.3±61.2; P = 0.001). Univariate analysis showed that the expression of PD-L1 in TC was associated with tumor T stage (P = 0.044) but not with serum Epstein-Barr virus (EBV) load (P = 0.816). On the other hand, the expression of PD-L1 in TIIC was related to both T stage (P = 0.028) and serum EBV load (P = 0.003). In multivariate logistic regression analysis, PD-L1 expression in TC was positively associated with tumor SUVmax (P = 0.003) and TLG (P = 0.001), while PD-L1 expression in TIIC was negatively associated with SUVmax (P = 0.038) and serum EBV load (P = 0.025). Through the ROC curve, the SUVmax cut-off value of 6.7 and the TLG cut-off value of 41.3 can be used to predict the PD-L1 status in TC with an accuracy of 78.6% and 71.4%, while the SUVmax cut-off value of 7.2 can be used to predict the PD-L1 status in TIIC with an accuracy of 72.6%.
Conclusions
18F-FDG uptake with NPC lesions were positively correlated with PD-L1 expression in TC and negatively correlated with PD-L1 expression in TIIC. 18F-FDG PET / CT imaging may be useful for predicting the PD-L1 status in patients with NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract